Advertisement

Somatostatin pp 303-311 | Cite as

Treatment of Diabetes with L363,586

  • J. Gerich
  • I. Gottesman
  • G. Bolli
  • P. Campbell
  • F. Kennedy
Part of the Serono Symposia, USA book series (SERONOSYMP)

Abstract

L363,586 (now referred to as MK-678) is a cyclic hexapeptide analog of somatostatin. This compound, whose amino acid sequence is shown in Figure 1, was developed by chemists at Merck, Sharp and Dohme Research laboratories on the basis of modeling of the active site of the somatostatin molecule in a project which involved the synthesis of more than 150 analogs (1).

Keywords

Growth Hormone Postprandial Hyperglycemia Regular Insulin Plasma Growth Hormone Postprandial Plasma Glucose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Veber D, Saperstein R, Nutt T, et al. A superactive cyclic hexapeptide analog of somatostatin. Life Sci 1984; 35: 1371.CrossRefGoogle Scholar
  2. 2.
    Gottesman I, Tobert J, Vandlen R, Gerich J. Efficacy, pharmacokinetics and tolerability of a somatostatin analog (L363,586) in insulin-dependent diabetes mellitus. Life Sci (in press).Google Scholar
  3. 3.
    Gerich J, Lorenzi M, Karam J, Schneider V, Forsham P. Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus. JAMA 1975; 234: 159.PubMedCrossRefGoogle Scholar
  4. 4.
    Campbell P, Bolli G, Gerich J. Prevention of the dawn phenomenon (early morning hyperglycemia) in insulin-dependent diabetes mellitus by a long-acting somatostatin analog. N Engl J Med (in press).Google Scholar
  5. 5.
    Bolli G, Gerich J. The dawn phenomenon—a common occurrence in both noninsulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med 1984; 310: 746.PubMedCrossRefGoogle Scholar
  6. 6.
    Bolli G, De Feo P, De Cosmo S, et al. Demonstration of a dawn phenomenon in normal human volunteers. Diabetes 1984; 33: 1150.PubMedCrossRefGoogle Scholar
  7. 7.
    Campbell P, Bolli G, Cryer P, Gerich J. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. N Engl J Med 1985; 312: 1473.PubMedCrossRefGoogle Scholar
  8. 8.
    Brennan J, Gebhart S, Blackard W. Pump-induced insulin aggregation: a problem with the BiostatorT’. Diabetes 1985; 34: 353.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • J. Gerich
    • 1
  • I. Gottesman
    • 1
  • G. Bolli
    • 1
  • P. Campbell
    • 1
  • F. Kennedy
    • 1
  1. 1.Endocrine Research UnitMayo ClinicRochesterUSA

Personalised recommendations